InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Explore the full record of transactions filed by Scherle Peggy, Directeur Scientifique. Director active across 1 companies, notably Prelude Therapeutics Inc. Cumulatively, 8 disclosures have been published. The latest transaction was disclosed on 26 August 2021 — Levée d'options. Regulator: SEC (Form 4). The full history is free.
Declarations8 total
€2,0681,700 shares@ €1.21640.0006% mcap5.3% of flow
Common Stock
SEC:0001209191-21-053867·
€2,0681,700 shares@ €1.21640.0006% mcap2.7% of flow
Common Stock
SEC:0001209191-21-053867:0·
€899558 shares@ €1.61040.0003% mcap2.3% of flow
Common Stock
SEC:0001209191-21-051885·
€899558 shares@ €1.61040.0003% mcap1.2% of flow
Common Stock
SEC:0001209191-21-051885:0·
€24,19020,000 shares@ €1.20950.0068% mcap62.0% of flow
Common Stock
SEC:0001209191-21-048688·
€24,19020,000 shares@ €1.20950.0068% mcap31.0% of flow
Common Stock
SEC:0001209191-21-048688:0·
€11,84910,000 shares@ €1.18490.0033% mcap30.4% of flow
Common Stock
SEC:0001209191-21-031847·
€11,84910,000 shares@ €1.18490.0033% mcap15.2% of flow
Common Stock
SEC:0001209191-21-031847:0·
8 of 8 declarations
About Scherle Peggy
Peggy Scherle is the Chief Scientific Officer at Prelude Therapeutics Inc, a biopharmaceutical company. She is responsible for leading research and development initiatives aimed at innovating in the field of medical treatments.
